BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 36210836)

  • 1. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
    Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
    Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
    Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
    Front Genet; 2022; 13():969856. PubMed ID: 36226187
    [No Abstract]   [Full Text] [Related]  

  • 5. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance.
    Chen W; Li X; Jiang Y; Ni D; Yang L; Wu J; Gao M; Wang J; Song J; Shi W
    Sci Rep; 2023 Nov; 13(1):19209. PubMed ID: 37932473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
    Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
    Front Genet; 2022; 13():962028. PubMed ID: 36061184
    [No Abstract]   [Full Text] [Related]  

  • 8. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
    Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
    Front Genet; 2022; 13():923737. PubMed ID: 35991547
    [No Abstract]   [Full Text] [Related]  

  • 9. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
    Liu Z; Miao J
    Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
    Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
    Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
    Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
    Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
    Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
    Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
    Wang L; Cao Y; Guo W; Xu J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance.
    Yang L; Zhang Y; Tang Y; Wang Y; Jiang P; Liu F; Feng N
    Sci Rep; 2023 Apr; 13(1):5779. PubMed ID: 37031216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
    Dai L; Zhou P; Lyu L; Jiang S
    BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
    Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.